Accueil / Communiqués / Titan Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

Titan Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

Wednesday, November 7th 2018 at 1:30pm UTC

TORONTO–(BUSINESS WIRE)– Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq:
TMDI)
, a medical device company focused on the design, development
and commercialization of a robotic surgical system for application in
single-port minimally invasive surgery (“MIS”), today announced that
David McNally, President and CEO of the Company, will present a
corporate overview at the Canaccord Genuity Medical Technologies &
Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern time.
The Medical Technologies & Diagnostics Forum will be held November 15,
2018 at the Westin Grand Central in New York, NY.

Mr. McNally’s presentation will be webcast live and available for replay
in the Investors section of Titan Medical’s website at titanmedicalinc.com/investors.

About Titan Medical

Titan Medical Inc. is focused on research and development through to the
planned commercialization of computer-assisted robotic surgical
technologies for application in minimally invasive surgery. The Company
is developing the SPORT Surgical System, a single-port robotic surgical
system. The SPORT Surgical System is comprised of a surgeon-controlled
patient cart that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface to the
patient cart and a 3D endoscopic view inside the patient’s body. Titan
intends to initially pursue focused surgical indications for the SPORT
Surgical System, which may include one or more of gynecologic, urologic,
colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com.

Contacts

LHA Investor Relations
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
or
Bruce
Voss, (310) 691-7100
bvoss@lhai.com

Source: Titan Medical Inc.


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …